ModifiedUnitedHealthcarePolicy CS198PA.H

Chemotherapy Observation or Inpatient Hospitalization (for Pennsylvania Only)

Defines when chemotherapy administration requires facility observation or inpatient hospitalization for members in Pennsylvania aged 18 and over, and lists regimens and clinical conditions that typically require inpatient care. Applies to UnitedHealthcare Pennsylvania policies and providers delivering chemotherapy.

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization (for Pennsylvania Only)

Policy CodePolicy CS198PA.H

Change TypeRevised regimen requirementsadded cross-reference

Effective DateJun 1, 2026

Next Review Date

Key ActionConsult the Pennsylvania-specific Hospital Services: Observation and Inpatient policy and plan terms for prior authorization requirements when claiming an inpatient stay for chemotherapy.

SourceLink

POLICY UPDATE CHANGES

Added reference link to the Medical Policy titled Hospital Services: Observation and Inpatient (for Pennsylvania Only).

Revised drug regimen requirements for an inpatient stay; removed list of applicable cancer type(s) for the listed regimens.

Updated Clinical Evidence and References sections to reflect the most current information and archived previous policy version CS198PA.G.

PennsylvaniaState

Adults onlyPopulation

Multiple

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Inpatient vs Observation

Inpatient medical necessity criteria

Inpatient stay is medically necessary for drug regimens that require inpatient monitoring or complex administration over multiple days when ALL specified regimen or monitoring factors are present.

Regimens requiring inpatient monitoring: EPOCH, DA-EPOCH, or R-EPOCH; ESHAP or R-ESHAP; Interleukin-2 infusion; High-dose ifosfamide (>1 g/m2/day); High-dose methotrexate (>500 mg/m2) with leucovorin rescue; Hyper-CVAD (specified cycles) — each regimen is described in the policy with drug doses and schedules.

These regimens are listed because they involve continuous infusions, multiple drugs/infusions over ~96 hours, or require close serum level or physiologic monitoring.

Factors contributing to inpatient stay: Coordination of multiple infusions or multiple drugs over 96 hours; need for continuous cardiac monitoring (IL-2); close monitoring of serum electrolytes, creatinine, bilirubin, urine output; vasopressor support; monitoring of serum methotrexate levels; bladder irrigation for cyclophosphamide; alkalinization of urine for ifosfamide.

Presence of these monitoring/administration requirements supports inpatient status for the listed regimens.

Observation criteria

Observation stay may be appropriate for certain chemotherapy-related clinical conditions or complications when monitoring for specific issues is needed but full inpatient admission is not indicated.

Observation conditions: Congestive heart failure or chronic renal failure requiring high-volume fluid infusions; known hypersensitivity reactions from previous infusion; TACE (Transcatheter Arterial Chemoembolization) or intra-arterial chemotherapy infusion.

These conditions may require an observation stay rather than inpatient admission depending on severity and monitoring needs.

Specified inpatient-only conditions

The following clinical conditions are listed as requiring inpatient hospital stay.

Inpatient-only conditions: Acute leukemia; intra-arterial infusion of chemotherapy; prophylaxis of tumor lysis syndrome in cases of high-grade lymphoma with large masses.

These conditions are explicitly identified as requiring inpatient hospitalization.

Inpatient vs Observation — revised regimen requirements and cross-reference

Coverage rationale and inpatient-stay drug regimen requirements were revised; providers must consult the linked Pennsylvania Hospital Services policy for inpatient vs observation determinations.

Inpatient stay requirements (summary): Drug regimen requirements for an inpatient stay were revised and lists of applicable cancer types for regimens were removed; specific criteria and operational guidance are available in the Pennsylvania-specific 'Hospital Services: Observation and Inpatient' policy and related plan terms.

Detailed AND/OR logic for when inpatient hospitalization is appropriate is not present in this excerpt; consult the related Pennsylvania policy and applicable federal/state/contractual benefit terms for prior authorization and coverage determination.

This policy applies only to adults. Individuals under 18 years of age are excluded from the scope of this document; the policy statements and coverage criteria are intended for members aged 18 and older.

FDA approval is informational only and does not by itself establish coverage. FDA approval alone is not a basis for coverage; coverage determinations require application of the policy’s medical necessity criteria and any applicable plan or contractual terms.

If a requested condition or treatment does not meet the policy’s listed criteria, the request will be reviewed individually. Such cases are evaluated on a case-by-case basis and may be considered not medically necessary if the submitted clinical information does not satisfy the applicable medical necessity standards (see InterQual® LOC guidance referenced in the policy).

Coverage determinations require more than regulatory approval; they must meet the policy’s defined medical necessity and any plan-specific terms. Decisions must be based on policy or plan-based medical necessity beyond FDA approval, and when applicable should reference federal, state, or contractual benefit provisions used to determine coverage.

Regimens That Typically Require Inpatient Monitoring

Regimen	Drugs / dosing (key elements)	Factors contributing to inpatient stay	Coverage status
EPOCH, DA-EPOCH, or R-EPOCH
Etoposide 50 mg/m2/day continuous infusion days 1–4; prednisone; vincristine IV days 1–4; cyclophosphamide 750 mg/m2 IV on day 5; doxorubicin 10 mg/m2/day continuous infusion days 1–4; with or without rituximab
Coordination of multiple infusions or multiple drugs over ~96 hours (multi-day continuous infusions requiring monitoring)
Covered with criteria

Regimen	Drugs / dosing (key elements)	Factors contributing to inpatient stay	Coverage status
ESHAP or R-ESHAP
Etoposide 40 mg/m2/day continuous infusion days 1–4; methylprednisolone; cytarabine (2 g/m2); cisplatin 25 mg/m2 continuous infusion days 1–4; with or without rituximab
Coordination of multiple infusions or multiple drugs over ~96 hours; monitor for CNS toxicity with cytarabine
Covered with criteria

Regimen / Protocol	Drugs / dosing (key elements)	Factors contributing to inpatient stay	Coverage status
Hyper‑CVAD
Cycles 1,3,5,7: cyclophosphamide 300 mg/m2 IV every 12 hours for six doses; mesna 600 mg/m2/day continuous infusion days 1–3; vincristine; doxorubicin 50 mg/m2 IV on day 4; dexamethasone. Cycles 2,4,6,8: methotrexate 200 mg/m2 IV over 2 hours followed by 800 mg/m2 IV over 22 hours on day 1 plus cytarabine 3 g/m2 (1 g/m2 if >60 years) IV over 2 hours every 12 hours for four doses starting on day 2; leucovorin per protocol
Coordination of multiple infusions over ~96 hours; bladder irrigation with cyclophosphamide; close monitoring of serum methotrexate levels
Covered with criteria

Item	Summary	Operational note / where to find details	Coverage status
Regimen-specific inpatient requirements (removed list)
Detailed regimen-specific inpatient requirement list was removed in this policy version; drug regimen requirements for inpatient stay were revised and prior lists of applicable cancer types were removed.
Providers should consult the Pennsylvania-specific Medical Policy titled 'Hospital Services: Observation and Inpatient (for Pennsylvania Only)' and applicable plan terms for operational prior authorization and inpatient vs observation determinations
Coverage decisions: mixed (see Pennsylvania policy and plan terms)

Coding and Numerical Thresholds

No explicit codes in this excerptmixed

No codes listed

Numeric Thresholds

Numeric thresholdsNo numeric thresholds specified in this excerpt.

ImplicationNo dosage, laboratory, or duration numeric cutoffs are provided as strict coverage thresholds in this policy excerpt.

Reference guidanceProviders must reference federal, state, or contractual requirements for any numeric criteria when applicable.

Provider Actions, Authorization, and Documentation

Prior Authorization

Pennsylvania application and case-by-case review

This Medical Policy only applies to the state of Pennsylvania. Any requests for services that do not meet criteria set in the PARP will be evaluated on a case-by-case basis. Refer to Pennsylvania Exceptions, Pennsylvania Code, Title 55, Chapter 1101.

Denial Risk

Denial risk for nonconforming requests

Requests that do not meet the criteria in this policy or the Pennsylvania-specific PARP may be denied. Providers should ensure submitted requests include all required clinical documentation and justification for inpatient care to reduce denial risk.

Denial risk for nonconforming requests: requests not meeting policy criteria may be denied

Note

Background and Clinical Context

Chemotherapy and other antineoplastic therapy can be given in settings ranging from home or outpatient clinics to facility observation units or inpatient hospitals. The choice of site of care depends on regimen complexity, duration of administration, and patient-specific monitoring needs. Inpatient hospitalization is indicated when regimens require complex multi-day administration or intensive monitoring (for example, continuous infusions, coordination of multiple drugs/infusions over ~96 hours, or the need for close serum-level and physiologic surveillance). Examples of such regimens and factors include multi-day continuous infusions and requirements for monitoring of electrolytes, urine output, cardiac status, or drug levels.

Definitions

Definition: TACE

TermTACE (Transcatheter Arterial Chemoembolization)

DefinitionA procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (National Cancer Institute, 2022).

ContextListed as a condition that may require an observation stay depending on monitoring needs.

Policy usageIncluded in Definitions to clarify observation vs inpatient decision-making for chemotherapy-related care.

Definition: Antineoplastic Therapy

Preferred terminologyAntineoplastic therapy (preferred term replacing 'chemotherapy' in 2024 ASCO-ONS standards).

Policy Revision History

2026-06-01material_revisionLatest

Revised drug regimen requirements for inpatient stay and removed the list of applicable cancer types for listed regimens; added a reference link to the Pennsylvania-only Medical Policy 'Hospital Services: Observation and Inpatient'.

2026-06-01supporting_info_updated

Updated Clinical Evidence and References sections and archived previous policy version CS198PA.G.